Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SUMO2 | P61956 | 1/20 | 0.30 |
| ▸ | SUMO1 | P63165 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP3 | Q9H4L4 | 1/20 | 0.30 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.30 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15845261 | 0.74 | — | — | |
| SCHEMBL29498953 | 0.71 | KMT2A (0.47) | MEN1KMT2AMYCPOLBRECQL | |
| SCHEMBL49341 | 0.71 | KMT2A (0.47) | MEN1KMT2AMYCPOLBRECQL | |
| SCHEMBL15430100 | 0.71 | MEN1 (0.40) | MEN1KMT2AMYCPOLBRECQL | |
| SCHEMBL11811420 | 0.70 | BRD4 (0.42) | MEN1KMT2AMYCPOLBRECQL | |
| SCHEMBL29145650 | 0.70 | KMT2A (0.46) | MEN1KMT2AMYCPOLBRECQL | |
| SCHEMBL151072 | 0.70 | MEN1 (0.42) | MEN1KMT2AMYCPOLBRECQL | |
| SCHEMBL27800085 | 0.70 | KMT2A (0.46) | MEN1KMT2AMYCPOLBRECQL | |
| Hydrochloric Acid SCHEMBL27917229 | 0.70 | KMT2A (0.46) | MEN1KMT2AMYCPOLBRECQL | |
| Water SCHEMBL27828657 | 0.70 | KMT2A (0.46) | MEN1KMT2AMYCPOLBRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622873-B1 | METHOD FOR PRODUCING RAC-1-{4-[2-HYDROXY-3-(5-QUINOLYLOXY)PROPYL]-PIPERAZIN-1-YL}-2,2-DIPHENYLETHAN-1-ONE FUMARATE | BAYER SCHERING PHARMA AG (DE) | 2010-01-13 | — | — | EP | claimed |
| US-5087773-A | Reacting with toluenesulfonic anhydride, contacting with telluride or selenide | SYRACUSE UNIVERSITY (US) | 1992-02-11 | — | — | US | claimed |
| EP-1438295-B1 | AZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK SERONO SA (CH) | 2012-08-15 | — | — | EP | disclosed |
| EP-2081910-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2012-02-01 | — | — | EP | disclosed |
| EP-2332922-A1 | N-substituted azoles and their use as MEK-1 and/or ERK-2 modulators | Merck Serono S.A. (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-7947727-B2 | Compounds | GlaxoGroupLimited (GB) | 2011-05-24 | — | — | US | disclosed |
| US-20100120883-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| EP-2081910-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2009-07-29 | — | — | EP | disclosed |
| US-7541375-B2 | Azole derivatives and pharmaceutical compositions containing them | LABORATOIRES SERONO SA (CH) | 2009-06-02 | — | — | US | disclosed |
| WO-2009050244-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009050221-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
| US-20060106073-A1 | Process for the preparation of epothilone derivatives, new epothilone derivatives as well as new intermediate products for the process and the methods of preparing same | NOVARTIS AG (CH) | 2006-05-18 | — | — | US | disclosed |
| EP-1539768-A2 | A NEW PROCESS FOR THE PREPARATION OF EPOTHILONE DERIVATIVES, NEW EPOTHILONE DERIVATIVES AS WELL AS NEW INTERMEDIATE PRODUCTS FOR THE PROCESS AND THE METHODS OF PREPARING SAME | Novartis AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-20050054706-A1 | Pharmaceutically active compounds and methods of use | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-03-10 | — | — | US | disclosed |
| EP-1438295-A2 | AZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Applied Research Systems ARS Holding N.V. (AN) | 2004-07-21 | — | — | EP | disclosed |
| WO-2004024735-A2 | A NEW PROCESS FOR THE PREPARATION OF EPOTHILONE DERIVATIVES, NEW EPOTHILONE DERIVATIVES AS WELL AS NEW INTERMEDIATE PRODUCTS FOR THE PROCESS AND THE METHODS OF PREPARING SAME | NOVARTIS AG (CH) | 2004-03-25 | — | — | WO | disclosed |
| WO-2003035626-A2 | AZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-05-01 | — | — | WO | disclosed |
| US-5866036-A | HIGH POLARIZATION; HIGH SPEED SWITCHES; HIGH BIREFRINGENCE | DISPLAYTECH, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5380460-A | Ferroelectric liquid crystal compounds containing chiral haloalkoxy tail units and compositions containing them | DISPLAYTECH, INC. (US) | 1995-01-10 | — | — | US | disclosed |
| WO-1993006192-A1 | FERROELECTRIC LIQUID CRYSTAL COMPOUNDS CONTAINING CHIRAL HALOALKOXY TAIL UNITS AND COMPOSITIONS CONTAINING THEM | DISPLAYTECH, INCORPORATED (US) | 1993-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054706-A1 | Pharmaceutically active compounds and methods of use | MAP3K1, MAPK1, MAP3K2 | MEN1 3337/4885KMT2A 3020/4885MYC 1490/4885 |
| US-20100120883-A1 | NOVEL COMPOUNDS | TSLP, LTB4R2, LTB4R | MEN1 4416/4885KMT2A 4335/4885MYC 2324/4885 |
| US-20060106073-A1 | Process for the preparation of epothilone derivatives, new epothilone derivatives as well as new intermediate products for the process and the methods of preparing same | EPOR, DHPS, POR | MEN1 1791/4885KMT2A 1280/4885MYC 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.